SHOP APOTHEKE EUROPE N.V.

  • WKN: A2AR94
  • ISIN: NL0012044747
  • Land: Niederlande

Nachricht vom 11.08.2021 | 23:26

DGAP-DD: SHOP APOTHEKE EUROPE N.V. english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
11.08.2021 / 23:26
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title:
First name: Jerome
Last name(s): Cochet

2. Reason for the notification

a) Position / status
Position: Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
SHOP APOTHEKE EUROPE N.V.

b) LEI
529900JK6UXHY1YKZ082 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: NL0012044747

b) Nature of the transaction
Acquisition

c) Price(s) and volume(s)
Price(s) Volume(s)
125.00 EUR 153750.00 EUR

d) Aggregated information
Price Aggregated volume
125.0000 EUR 153750.0000 EUR

e) Date of the transaction
2021-08-09; UTC+2

f) Place of the transaction
Name: Tradegate
MIC: TGAT



11.08.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021